Investigating the Use of Prolia (Denosumab) in the Treatment of Acute Charcot Neuroarthropathy
Phase of Trial: Phase III
Latest Information Update: 24 Oct 2019
Price : $35 *
At a glance
- Drugs Denosumab (Primary)
- Indications Peripheral neuropathies; Rheumatic disorders
- Focus Adverse reactions
- 22 Oct 2019 Status changed from active, no longer recruiting to completed.
- 03 Oct 2018 Planned End Date changed from 16 May 2020 to 6 Mar 2019.
- 03 Oct 2018 Status changed from recruiting to active, no longer recruiting.